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Abstract
Background: The control arm of PATRICIA (PApillomaTRIal against Cancer In young Adults, NCT00122681) was
used to investigate the risk of progression from cervical HPV infection to cervical intraepithelial neoplasia (CIN) or
clearance of infection, and associated determinants.
Methods and Findings: Women aged 15-25 years were enrolled. A 6-month persistent HPV infection (6MPI) was
defined as detection of the same HPV type at two consecutive evaluations over 6 months and clearance as ≥2 type-
specific HPV negative samples taken at two consecutive intervals of approximately 6 months following a positive
sample. The primary endpoint was CIN grade 2 or greater (CIN2+) associated with the same HPV type as a 6MPI.
Secondary endpoints were CIN1+/CIN3+ associated with the same HPV type as a 6MPI; CIN1+/CIN2+/CIN3+
associated with an infection of any duration; and clearance of infection. The analyses included 4825 women with
16,785 infections (3363 womenwith 6902 6MPIs). Risk of developing a CIN1+/CIN2+/CIN3+ associated with same
HPV type as a 6MPI varied with HPV type and was significantly higher for oncogenic versus non-oncogenic types.
Hazard ratios for development of CIN2+ were 10.44 (95% CI: 6.96-15.65), 9.65 (5.97-15.60), 5.68 (3.50-9.21), 5.38
(2.87-10.06) and 3.87 (2.38-6.30) for HPV-16, HPV-33, HPV-31, HPV-45 and HPV-18, respectively. HPV-16 or
HPV-33 6MPIs had ~25-fold higher risk for progression to CIN3+. Previous or concomitant HPV infection or CIN1+
associated with a different HPV type increased risk. Of the different oncogenic HPV types, HPV-16 and HPV-31
infections were least likely to clear.
Conclusions: Cervical infections with oncogenic HPV types increased the risk of CIN2+ and CIN3+. Previous or
concomitant infection or CIN1+ also increased the risk. HPV-16 and HPV-33 have by far the highest risk of
progression to CIN3+, and HPV-16 and HPV-31 have the lowest chance of clearance.
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Introduction
Persistent infection with oncogenic human papillomavirus
(HPV) is necessary for the development of cervical cancer [1].
Approximately 15 oncogenic HPV types have been identified to
date, of which HPV-16 and HPV-18 are the most prevalent in
cervical cancer, accounting for approximately 70% of cases
worldwide [2].
Many sexually active individuals become infected with HPV
after beginning their first sexual relationship [3]. HPV infections
are usually transient, and even those that persist for a few
months are usually cleared naturally. Development of cervical
intraepithelial neoplasia (CIN) and cervical cancer is almost
always preceded by a persistent oncogenic HPV infection [4,5].
Numerous determinants are thought to affect progression of
HPV infection to a CIN, including behavioural determinants
such as tobacco exposure, sexual intercourse with increased
numbers of partners, contraceptive use and previous
pregnancy [6–8], as well as immunosuppression and presence
of infections with other sexually-transmitted pathogens such as
Chlamydia trachomatis and herpes simplex virus [9–11]. CIN is
diagnosed from histological analysis of a cervical lesion. It is
categorised into three grades: CIN grade 1 (CIN1), grade 2
(CIN2) and grade 3 (CIN3) with CIN3 considered as the
immediate precursor to invasive cervical cancer (ICC) [12].
A better understanding is needed of the natural history of
progression of a cervical HPV infection to a CIN or to clearance
of the infection. Such analyses can be performed using the
control arm of large trials of prophylactic HPV vaccines where
data on HPV types, histological lesions and potential
determinants of disease progression are extensively collected.
The present paper reports the analysis of HPV infection and its
clearance or progression to CIN in the PApilloma Trial against
Cancer In young Adults (PATRICIA), a phase III trial of the
HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) in over
18,000 young women.
Methods
This analysis was based on data obtained from the control
arm of the double-blind, randomised, multinational (14
countries), controlled, 4-year PATRICIA trial
(NCT00122681/580299/008). The objectives were to
investigate the time between detection of an HPV infection
(through HPV genotyping) and development of a CIN lesion
associated with the same HPV type, and to evaluate
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PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e79260
determinants associated with disease progression or natural
clearance of infection.
Study population and procedures
The clinical trial methodology, including full inclusion and
exclusion criteria, trial locations and dates, has been described
previously [13,14]. Briefly, women aged 15–25 years with no
more than 6 lifetime sexual partners were enrolled in the study
and were randomised to HPV-16/18 AS04-adjuvanted vaccine
or control hepatitis A vaccine. HPV genotyping of cervical
liquid-based cytology samples was performed at baseline and
every 6 months throughout the 4-year study by polymerase
chain reaction (PCR). Cytological examination using the
Bethesda system was performed every 12 months and, when a
biopsy was performed by the physician, histological
classification was done. Oncogenic HPV types tested for were
HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68;
non-oncogenic types tested for were HPV-6, 11, 34, 40, 42, 43,
44, 53, 54, 70 and 74 [15].
Subjects completed a behavioural questionnaire [16]
including tobacco exposure, sexual intercourse and
contraceptive use at the second study visit, 1 month after the
first vaccination, and yearly during the follow-up period. For the
purpose of this analysis, the term sexual intercourse included
penetrative, non-penetrative genital-to-genital, or oral-genital
sexual contact.
Written informed consent or assent was obtained from all
participants or their parents, and the protocol and other
materials were approved by independent ethics committees or
institutional review boards (Table S1 in File S1).
Endpoint definitions
HPV infections were classified according to their duration as
a transient infection, a 6-month persistent infection (6MPI), a
12-month persistent infection (12MPI), a less than 6MPI, and
an infection detected only at the last visit of the study. A
transient infection was defined as detection of a specific HPV
type in a cervical sample at any single point during the follow-
up period, followed by a negative sample for the same HPV
type at the next evaluation. A 6MPI was defined as detection of
the same HPV type at two consecutive evaluations over a 6-
month period or greater i.e. a sequence of positive samples
with the same HPV type not interrupted by negative samples
over a total range of >5 months (>150 days). The start of the
6MPI was defined as the date of the first positive sample in the
sequence. A 12MPI was defined in the same way, over a 12-
month period. A less than 6MPI was defined as an infection
with duration ≤150 days, again with the same HPV type, not
interrupted by negative samples (although visits were
scheduled for every 6 months, in some cases there was less
time between consecutive visits, allowing a category of
persistent HPV infection of less than 6 months’ duration).
Clearance was defined as the occurrence of at least two
consecutive type-specific negative HPV DNA samples taken at
approximately a 6-month interval following a positive sample.
Although we recognise that apparent clearance could in reality
be an inability to detect the infection, we use the term
clearance for convenience.
Histologically confirmed lesions were detected in
colposcopically-directed biopsy samples or post-excision
samples following treatment and were categorised as CIN
grade 1 or greater (CIN1+), CIN grade 2 or greater (CIN2+)
and CIN grade 3 or greater (CIN3+). CIN1+ included CIN1,
CIN2, CIN3 and adenocarcinoma in situ (AIS) identified by
standard methods.
Statistical analysis
The primary endpoint was CIN2+ associated with the same
HPV type as a 6MPI. Secondary endpoints were CIN1+ and
CIN3+ associated with the same HPV type as a 6MPI; CIN1+,
CIN2+ and CIN3+ associated with the same HPV type as an
infection of any duration; and clearance of HPV infections.
Analysis cohort.  The analysis was performed in the control
group of the total vaccinated cohort for efficacy (TVC-E)
(Figure 1). The TVC-E included all women who received at
least one dose of control vaccine and had normal or low-grade
cytology at baseline (ie, negative, atypical squamous cells of
undetermined significance or low-grade squamous
intraepithelial lesion). The analysis population included only
women aged 15–25 years and only those in whom at least one
cervical HPV infection was detected during the study.
Infections in participants in whom HPV DNA was detected at
baseline but not at month 6 were classified as transient for the
purpose of the analysis. However, it must be noted that these
could have been persistent infections because the date of their
origin was unknown.
Determinants.  The main determinants of interest were HPV
type and duration of HPV infection. Covariates known to
influence the risk of acquiring HPV infection were also
accounted for in the analyses. Eight potential behavioural
characteristics were included in the models: tobacco exposure
measured as number of pack-years (one pack-year was
equivalent to 365 packs of cigarettes), age at first sexual
intercourse, number of sexual partners during the past 12
months, history of Chlamydia trachomatis during the past 12
months, marital/partner status, previous pregnancy, use of
hormones for contraception or other indication, and use of an
intrauterine device.
In addition, the models accounted for previous cervical HPV
infection with an oncogenic HPV type or with only non-
oncogenic HPV types (i.e. preceding the onset of the reference
infection), cervical HPV co-infection with an oncogenic HPV
type or with only non-oncogenic HPV types (i.e. following the
onset of the reference infection and preceding detection of the
lesion), previous CIN1+ lesion associated with any oncogenic
or non-oncogenic HPV type different to the reference infection
(i.e. CIN1+ preceding the onset of the reference infection), and
concomitant CIN1+ lesion associated with any oncogenic or
non-oncogenic HPV type different to the reference infection
(i.e. CIN1+ following the onset of the reference infection and
preceding its end). Cervical HPV co-infections and CIN1+
lesions associated with an HPV type different to the reference
HPV infection were included in the models as time-varying
covariates.
General statistical considerations.  The time between a
cervical HPV infection and development of a CIN lesion was
Natural History of Cervical HPV Infection
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analysed using the Kaplan-Meier method as well as univariate
and multivariable Cox regression models. The statistical unit
was the infection, and variance estimates adjusted for the
correlation within subjects were obtained using the robust
estimation method [17,18]. The same methods were used to
analyse natural clearance of HPV infection. All data were
censored at the last recorded visit or at 48 months, whichever
occurred first. Covariates with a p-value <0.2 in the univariate
model were included in the multivariable model, with the
exception of region which was always included regardless of
the p-value obtained. Infections or lesions with a missing value
for a covariate included in the analysis were excluded from the
multivariable analysis. All analyses were performed using SAS
version 9.2.
Results
Subject disposition and characteristics
A total of 9256 women in the TVC-E were aged 15–25 years
and had negative or low-grade cytology (Figure 1). Of these,
subjects with no cervical HPV infection during the study
(n=3794, 41.0%) or in whom an infection was detected only at
the last visit of the study (n=637, 6.9%) were excluded from the
analysis (Figure 1). A total of 4825 women with at least one
cervical HPV infection of any duration (16,785 infections)
during the 48 month follow-up were included. Of these, 3363
women had at least one 6MPI (6902 infections), 2283 had a
12MPI (3487 infections), 355 had persistent HPV infection(s) of
less than 6 months (449 infections), and 3945 had transient
HPV infection(s) (9434 infections). A total of 1285 women had
an infection detected at baseline but not at month 6 (classed as
a transient infection for the purpose of the analysis, although its
duration prior to study entry was unknown). The five most
prevalent HPV types were HPV-16 (9.3% of any infections and
13.9% of 6MPIs), HPV-18 (5.6% and 6.0%), HPV-31 (5.4% and
6.5%), HPV-33 (2.9% and 3.0%) and HPV-45 (2.3% and
2.2%). The prevalence of other oncogenic HPV types was
45.7% (any infection) and 47.4% (6MPI), and the prevalence of
non-oncogenic types was 28.7% (any infection) and 20.9%
(6MPI).
Among the subjects with at least one cervical HPV infection
of any duration, mean (SD) age was 19.7 (3.1) years, most
were single (74.4%), with no tobacco exposure (63.4%), had
started sexual intercourse between the ages of 15 and 17
years (51.8%), had one or no sexual partner during the past 12
months (71.3%), had not been pregnant (73.1%), had no
history of Chlamydia trachomatis (90.3%) and had used
Figure 1.  Subject disposition.  From the 9337 women enrolled in the control arm of the PATRICIA trial, 4512 were excluded from
the present analyses including 4431 subjects with no cervical HPV infection detected during the 48 months of follow-up. 4825
women representing 16785 cervical HPV infections (blue) were included and two sub-cohorts were constituted: women with a 6-
month persistent HPV infection (6MPI) (n = 3363 representing 6902 infections) (light blue) and women with a natural clearance of
the HPV infection (n = 4011 representing 10983 clearances) (light purple). The numbers of women and of CIN1+/CIN2+/CIN3+
lesions were calculated after exclusion of the lesions occurring after 48 months for any duration of HPV infection (blue) and for 6MPI
(light blue).
Among the 119 subjects with 6MPI and CIN3+, 9 had AIS (11 episodes). Among the 124 subjects with an infection of any duration
and CIN3+, 10 had AIS (13 episodes). No invasive cervical cancer was found.
6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; TVC-E: total vaccinated
cohort for efficacy.
doi: 10.1371/journal.pone.0079260.g001
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hormonal contraception (65.4%) (Table 1). Characteristics of
subjects in whom at least one 6MPI was detected were similar.
Table 1. Frequency distribution of age, region and other determinants at baseline according to duration of cervical HPV
infection.
Determinant Category 6MPI HPV infection (any duration)
  N=3363 N=4825
Age (years) Mean (SD) 19.5 (3.0) 19.7 (3.1)
 Median (range) 19 (15–25) 19 (15–25)
Age group, n (%) 15-17 years 1322 (39.3) 1753 (36.3)
 18-25 years 2041 (60.7) 3072 (63.7)
Region, n (%) Europe 1422 (42.3) 1874 (38.8)
 Asia Pacific 767 (22.8) 1229 (25.5)
 North America 568 (16.9) 857 (17.8)
 Latin America 606 (18.0) 865 (17.9)
Marital/partner status, n (%) Single 2595 (77.2) 3591 (74.4)
 Living or lived with partner2 733 (21.8) 1178 (24.4)
 Missing 35 (1.0) 56 (1.2)
Tobacco exposure (number of pack-years), n (%) None or less than 6 months (<0.5) 2031 (60.4) 3058 (63.4)
 At least 6 months (≥0.5) 1296 (38.5) 1713 (35.5)
 Missing 36 (1.1) 54 (1.1)
Age at first sexual intercourse, n (%) Never had sexual intercourse 3 (0.1) 26 (0.5)
 ≥26 3 (0.1) 6 (0.1)
 18-25 996 (29.6) 1525 (31.6)
 15-17 years 1790 (53.2) 2497 (51.8)
 <15 years 569 (16.9) 763 (15.8)
 Missing 2 (0.1) 8 (0.2)
Number of sexual partners during the past 12 months, n (%) 0–1 2294 (68.2) 3441 (71.3)
 2-3 869 (25.8) 1132 (23.5)
 ≥4 193 (5.7) 238 (4.9)
 Missing 7 (0.2) 14 (0.3)
Previous pregnancy, n (%) Yes 817 (24.3) 1281 (26.6)
 No 2539 (75.5) 3527 (73.1)
 Missing 7 (0.2) 17 (0.4)
At least one delivery, n (%) Yes 516 (15.3) 814 (16.9)
 No 2837 (84.4) 3991 (82.7)
 Missing 10 (0.3) 20 (0.4)
History of Chlamydia trachomatis during the past 12 months, n (%) Yes 344 (10.2) 468 (9.7)
 No 3018 (89.7) 4355 (90.3)
 Missing 1 (0.03) 2 (0.04)
Contraceptive use [1], n (%) Abstinent or no contraception 1032 (30.7) 1535 (31.8)
 Hormonal 2253 (67.0) 3155 (65.4)
 Intra-uterine device 146 (4.3) 221 (4.6)
 Sterilised 25 (0.7) 38 (0.8)
History of sexual intercourse at study entry Yes 3114 (92.6) 4426 (91.7)
 No 242 (7.2) 385 (8.0)
 Missing 7 (0.2) 14 (0.3)
History of sexual intercourse at the end of the study Yes 3359 (99.9) 4798 (99.4)
 No 3 (0.1) 26 (0.5)
 Missing 1 (0.03) 1 (0.02)
1 Women could be using more than one method of contraception.
2 Living with or had lived with partner included married, living with partner, widowed, divorced, separated.
6MPI: 6-month persistent infection; HPV: human papillomavirus
doi: 10.1371/journal.pone.0079260.t001
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Risk of Developing a CIN Lesion Associated with a 6-
Month Persistent Infection
The number of women with a 6MPI who developed a CIN1+,
CIN2+ or CIN3+ lesion during the study is shown in Figure 1.
Lesions that developed after Month 48 were not included in the
analysis. The multivariable analysis showed that, for women
with a 6MPI, the cumulative risk of developing a CIN1+, CIN2+
or CIN3+ lesion associated with the same HPV type
significantly increased for an infection with the five most
prevalent HPV types (HPV-16/18/31/33/45) or with any other
oncogenic type compared with a non-oncogenic HPV type
(Table 2; Figures 2a and 2b). Compared with women with a
non-oncogenic HPV 6MPI, women with HPV-16 or HPV-33
6MPIs had approximately a 25-fold higher risk for progression
to a CIN3+ lesion, those with a HPV-31 6MPI had a 10-fold
higher risk, those with HPV-18 and HPV-45 6MPIs had a 6-fold
higher risk, and those with 6MPIs with any other oncogenic
type had a 4-fold higher risk. The association between a 6MPI
with an oncogenic HPV type and development of a lesion
became stronger as lesion severity increased; for example, the
Hazard Ratio (HR) from the multivariable analysis for HPV-16
increased from 4.60 for CIN1+ to 10.44 for CIN2+ and to 26.82
for CIN3+.
A previous infection with an oncogenic HPV type different
from the 6MPI significantly increased the risk of CIN1+
(previous infection was not included in the multivariable
analysis for CIN2+ and CIN3+ because a p-value of >0.2 was
obtained in the univariate analysis) (Table 2). Presence of a co-
infection with a different oncogenic HPV type also significantly
increased the risk of developing CIN1+ or CIN2+, but not
CIN3+ (Table 2). A CIN1+ lesion associated with a different
oncogenic HPV type also significantly increased the risk of
CIN1+, CIN2+ or CIN3+, regardless of whether it occurred prior
to or concomitant with the 6MPI.
Results of the univariate and multivariable analyses of the
risk of developing a CIN lesion that account for behavioural
determinants are shown in Tables S2–S4 in File S1.
Behavioural determinants that were significant (p<0.05) in the
multivariable analysis were tobacco exposure and previous
pregnancy for CIN1+, previous pregnancy and use of
hormones for contraception or other indication for CIN2+, and
previous pregnancy and age at first sexual intercourse for
CIN3+.
Risk of developing a CIN lesion associated with an HPV
infection of any duration
HPV-16, HPV-51 and HPV-52 were the most frequent HPV
types observed (1557, 1613 and 1374 infections, respectively),
with HPV-16 being the most frequently detected in CIN1+ and
CIN2+. As observed for 6MPIs, in the multivariable analysis,
the association between an infection of any duration with an
oncogenic HPV type and development of a lesion became
stronger as lesion severity increased (Table 3). Again, the risk
of developing a CIN lesion associated with the same HPV type
was higher for HPV-16, HPV-33, HPV-31, HPV-18 and
HPV-45, any other oncogenic HPV type compared with non-
oncogenic HPV types; the highest risk was for HPV-16 and
HPV-33 (approximately 20-fold), followed by HPV-31 (8-fold),
and then by HPV-18 or HPV-45 (4.5-fold) (Table 3).
The duration of the HPV infection had a marked impact on
the risk of developing a lesion, with a 6MPI showing the highest
risk for CIN lesion development, followed by a persistent
infection of less than 6 months duration, while a transient HPV
infection showed the lowest risk (Table 3). Compared with a
transient infection, both persistent infections of less than 6
months duration and 6MPIs were significantly associated with
higher risk of CIN1+ (HR: 2.48 and 4.25, respectively) and
CIN2+ (HR: 2.32 and 4.61, respectively); only 6MPI was
significantly associated with increased risk of CIN3+ (HR:
5.29).
Co-infection with an oncogenic HPV type different from the
reference infection significantly increased the risk of developing
CIN1+, CIN2+ or CIN3+ (Table 3). A previous infection with a
different oncogenic HPV type also increased the risk of CIN1+
and CIN2+ (the analysis was not performed for CIN3+ because
this covariate was not statistically significant (p>0.2) in the
univariate model). A previous or concomitant CIN1+ lesion
associated with a different oncogenic HPV type also
significantly increased the risk of lesion development.
Results of the univariate and multivariable analyses of the
risk of developing a CIN lesion that account for behavioural
determinants are shown in Tables S5–S7 in File S1.
Behavioural determinants that were significant (p<0.05) in the
multivariable analysis were tobacco exposure and previous
pregnancy for CIN1+, previous pregnancy and use of
hormones for contraception or other indication for CIN2+, and
previous pregnancy for CIN3+.
Clearance of HPV infection
Overall, 53%, 79%, 87% and 89% of all HPV infections were
cleared at 12, 24, 36 and 48 months, respectively (Figure 3a).
The median time to clearance for transient HPV infections and
6MPIs was 6.26 months and 18.85 months, respectively (Table
4). HPV-16 and HPV-31 were significantly less likely to clear
than a non-oncogenic HPV type, and other oncogenic HPV
types had an intermediate chance of clearance (Figure 3b;
Table 4). Previous infection with the same or with other HPV
types reduced the chance of clearance; in contrast, the chance
of clearance was increased by co-infection with another
oncogenic HPV type in this analysis.
Results of the univariate and multivariable analyses of
clearance of HPV infection that account for behavioural
determinants are shown in Table S8 in File S1. Determinants
that were significant (p<0.05) in the multivariable analysis were
region and marital status (the chance of clearance was lower in
women who were living or had lived with a partner than in
single women).
The results for prevalence, risk of progression to CIN and
chance of clearance are summarised according to HPV type in
Figure 4. HPV-16 has a high prevalence, high risk of
progression and low chance of clearance, and is thus overall
the most high-risk HPV type. HPV-33 shows a lower
prevalence, a high risk of progression and a medium chance of
clearance. HPV-31 has a medium prevalence, a medium risk of
progression and a low chance of clearance. HPV-18 has a
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consistently medium prevalence, progression and clearance.
Findings for the other HPV types are less consistent.
Discussion
The analysis evaluated the risk of progression to CIN lesion
and the chance of clearance according to HPV type. The role
of HPV types and persistent infection as the main risk factors
for CIN lesion were confirmed and the results also showed the
roles of previous infection and co-infection with an oncogenic
HPV type, as well as previous or concomitant CIN1+, as risk
factors for progression to CIN in young women. Our large
sample size allowed for the first time calculation of the risk of
progression of HPV infection to CIN3+. Previous studies have
Table 2. Multivariable analysis of the risk of progression of a 6MPI infection to a CIN lesion associated with the same HPV
type.
 CIN1+ CIN2+ CIN3+
 Hazard ratio1 (95% CI) p-value Hazard ratio1 (95% CI) p-value Hazard ratio1 (95% CI) p-value
 6835 infections in 3337 women 6835 infections in 3337 women 6785 infections in 3325 women
 818 lesions2 464 lesions2 152 lesions2
HPV type
Non-oncogenic type 1 - 1 - 1 -
HPV-16 4.60 (3.47–6.09) <0.0001 10.44 (6.96–15.65) <0.0001 26.82 (10.00–71.94) <0.0001
HPV-18 2.43 (1.70–3.48) <0.0001 3.87 (2.38–6.30) <0.0001 6.04 (1.82–20.04) 0.0033
HPV-31 3.33 (2.39–4.64) <0.0001 5.68 (3.50–9.21) <0.0001 9.80 (3.16–30.37) <0.0001
HPV-33 4.44 (3.12–6.32) <0.0001 9.65 (5.97–15.60) <0.0001 25.04 (9.00–69.69) <0.0001
HPV-45 2.53 (1.53–4.17) 0.0003 5.38 (2.87–10.06) <0.0001 6.88 (1.54–30.74) 0.0116
Other oncogenic type 2.16 (1.66–2.81) <0.0001 2.80 (1.87–4.19) <0.0001 3.73 (1.34–10.37) 0.0117
 <0.0001 <0.0001 <0.0001
Previous cervical HPV infection3
No 1 - Not included Not included
Yes (at least 1 oncogenic HPV type) 1.32 (1.11–1.56) 0.0016     
Yes (only non-oncogenic HPV types) 1.15 (0.78–1.70) 0.4846     
 0.0071     
Cervical HPV co-infection4,5
No 1 - 1 - 1 -
Yes (at least 1 oncogenic HPV type) 1.75 (1.44–2.12) <0.0001 1.88 (1.46–2.41) <0.0001 1.36 (0.94–1.98) 0.1018
Yes (only non-oncogenic HPV types) 1.05 (0.76–1.46) 0.7689 0.80 (0.49–1.31) 0.3731 0.74 (0.33–1.66) 0.4657
 <0.0001 <0.0001 0.0955
Previous CIN1+6
No 1 - 1 - 1 -
Yes (at least 1 oncogenic HPV type) 1.94 (1.21–3.12) 0.0059 2.75 (1.58–4.80) 0.0004 3.78 (1.69–8.41) 0.0012
Yes (only non-oncogenic HPV types) -  - - - -
 0.0059 0.0004 0.0012
Concomitant CIN1+5,7
No 1 - 1 - 1 -
Yes (any oncogenic or non-oncogenic HPV type) 2.27 (1.67–3.08) <0.0001 2.03 (1.40–2.93) 0.0002 3.86 (2.31–6.47) <0.0001
 <0.0001 0.0002 <0.0001
1 Covariates were included in the multivariable analysis if they had a global p-value of <0.2 in the univariate analysis (except region which was always included); covariates
were: region, smoking, age at first sexual intercourse, number of sexual partners during the past 12 months, history of Chlamydia trachomatis during the past 12 months,
marital/partner status, previous pregnancy, use of hormones for contraception or other indication, use of intrauterine device, previous or concomitant HPV co-infections,
previous or concomitant CIN1+. Refer to Tables S2–S4 for more detail.
2 Infections or lesions with a missing value for a covariate included in the analysis were excluded from the multivariable analysis.
3 Preceding the onset of the reference infection.
4 Following the onset of the reference infection and preceding detection of the lesion.
5 Time-varying covariate.
6 CIN1+ associated with an HPV type different to the reference infection, preceding the onset of the 6MPI.
7 CIN1+ associated with an HPV type different to the reference infection, concomitant to the 6MPI (following its onset and preceding its end).
Values in italics show the global p-value.
6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus
doi: 10.1371/journal.pone.0079260.t002
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been limited in their sample size and number of infections
evaluated, and largely focused on development of invasive
cervical cancer in adult women.
The five most prevalent HPV types were HPV-16, HPV-31,
HPV-18, HPV-33 and HPV-45. The risk of developing a CIN
lesion was higher following infection with oncogenic HPV types
than with non-oncogenic types, the highest risk being with
HPV-16 and HPV-33 (up to 10-fold higher for CIN2+ and up to
25-fold higher for CIN3+ compared with non-oncogenic types),
followed by HPV-31, HPV-45 and HPV-18. The association
between an infection with an oncogenic HPV type and the risk
of CIN became stronger as lesion severity increased, reflecting
the increasing prevalence of HPV types belonging to the A7
and A9 HPV species as lesion severity increases (the A7
Figure 2.  Risk of progression of a 6MPI to CIN2+ or CIN3+ associated with the same HPV type.  2a. CIN2+
2b. CIN3+
Kaplan–Meier Estimates of Cumulative Risk (%) of Developing CIN2+ Lesions (Figure 2a) or CIN3+ Lesions (Figure 2b) Associated
with the Same HPV Type Were Calculated for HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, Other Oncogenic HPV Types and Non-
Oncogenic HPV Types
doi: 10.1371/journal.pone.0079260.g002
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species includes HPV-18 and HPV-45, while the A9 species
includes HPV-16, HPV-31 and HPV-33).
Our findings reflect those of other studies evaluating
prevalence of different HPV types in cervical cancer and the
risk of progression from infection to pre-cancerous lesions or
Table 3. Multivariable analysis of the risk of progression of an HPV infection of any duration to a CIN lesion associated with
the same HPV type.
 CIN1+ CIN2+ CIN3+
 Hazard ratio1 (95% CI) p-value Hazard ratio1 (95% CI) p-value Hazard ratio1 (95% CI) p-value
 16580 infections in 4789 Women 16580 infections in 4789 women 16596 infections in 4791 women
 1069 lesions2 577 lesions2 180 lesions2
HPV type
Non-oncogenic type 1 - 1 - 1 -
HPV-16 4.39 (3.52–5.47) <0.0001 9.25 (6.84–12.51) <0.0001 20.93 (9.97–43.95) <0.0001
HPV-18 2.47 (1.85–3.30) <0.0001 3.56 (2.40–5.27) <0.0001 4.74 (1.78–12.58) 0.0018
HPV-31 3.34 (2.57–4.34) <0.0001 5.09 (3.56–7.29) <0.0001 7.82 (3.46–17.63) <0.0001
HPV-33 4.36 (3.29–5.79) <0.0001 9.14 (6.34–13.18) <0.0001 20.47 (9.45–44.35) <0.0001
HPV-45 2.28 (1.49–3.49) 0.0002 3.64 (2.08–6.40) <0.0001 4.45 (1.17–16.97) 0.0286
Other oncogenic type 2.19 (1.79–2.67) <0.0001 2.63 (1.94–3.57) <0.0001 3.51 (1.62–7.59) 0.0014
 <0.0001 <0.0001 <0.0001
Duration of infection
Transient 1 - 1 - 1 -
Less than 6MPI 2.48 (1.54–3.98) 0.0002 2.32 (1.22–4.40) 0.0102 1.45 (0.32–6.48) 0.6275
6MPI 4.25 (3.63–4.97) <0.0001 4.61 (3.66–5.81) <0.0001 5.29 (3.34–8.38) <0.0001
 <0.0001 <0.0001 <0.0001
Previous cervical HPV infection3
No 1 - 1 - Not included
Yes (at least 1 oncogenic HPV type) 1.52 (1.31–1.77) <0.0001 1.27 (1.03–1.57) 0.0254   
Yes (only non-oncogenic HPV types) 1.22 (0.85–1.73) 0.2791 1.21 (0.75–1.96) 0.4324   
 <0.0001 0.0803   
Cervical HPV co-infections4,5
No 1 - 1 - 1 -
Yes (at least 1 oncogenic HPV type) 1.85 (1.54–2.21) <0.0001 1.93 (1.52–2.45) <0.0001 1.40 (0.99–1.99) 0.0595
Yes (only non-oncogenic HPV types) 0.99 (0.73–1.34) 0.9366 0.76 (0.48–1.20) 0.2375 0.60 (0.27–1.33) 0.2110
 <0.0001 <0.0001 0.0243
Previous CIN1+ 6
No 1 - 1 - 1 -
Yes (any oncogenic or non-oncogenic HPV type) 2.32 (1.59–3.40) <0.0001 2.74 (1.73–4.32) <0.0001 3.65 (1.76–7.54) 0.0005
 <0.0001 <0.0001 0.0005
Concomitant CIN1+5,7
No 1 - 1 - 1 -
Yes (any oncogenic or non-oncogenic HPV type) 2.76 (2.10–3.63) <0.0001 2.65 (1.89–3.71) <0.0001 4.70 (2.77–7.99) <0.0001
 <0.0001 <0.0001 <0.0001
1 Covariates were included in the multivariable analysis if they had a global p-value of <0.2 in the univariate analysis (except region which was always included); covariates
were: region, smoking, age at first sexual intercourse, number of sexual partners during the past 12 months, history of Chlamydia trachomatis during the past 12 months,
marital/partner status, previous pregnancy, use of hormones for contraception or other indication, use of intrauterine device, previous or concomitant HPV co-infections,
previous or concomitant CIN1+. Refer to Tables S5–S7 for more detail.
2 Infections or lesions with a missing value for a covariate included in the analysis were excluded from the multivariable analysis.
3 Preceding the onset of the reference infection.
4 Following the onset of the reference infection and preceding detection of the lesion.
5 Time-varying covariate.
6 CIN1+ associated with an HPV type different to the reference infection, preceding the onset of the 6MPI.
7 CIN1+ associated with an HPV type different to the reference, concomitant to the 6MPI (following its onset and preceding its end).
Values in italics show the global p-value.
6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus
doi: 10.1371/journal.pone.0079260.t003
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cancer. A US-based case-control study showed that the most
prevalent HPV types in ICC and carcinoma in situ are
HPV-16/18/45 and HPV-16/31/33, respectively [19]. An
international cross-sectional study of HPV genotype attribution
confirmed that the most prevalent oncogenic HPV types in ICC
are HPV-16/18/31/33/35/45/52/58 [2]. Schiffman and
colleagues have hypothesised that infections with HPV-16 are
most likely to persist and progress to pre-cancerous and
cancerous lesions [20]. A population-based screening
programme has shown that the risk of progression to CIN2+ is
similar for women infected by HPV-16 and HPV-33 [21].
Similarly, more recent data from the control arm of the
Figure 3.  Cumulative chance of clearing a cervical HPV infection (prevalent and incident infections).  3a. Duration of
infection
3b. HPV type (infection of any duration)
Kaplan–Meier estimates of probability of clearance (%) were calculated for transient, less than 6-month persistent HPV infection
(6MPI), 6MPI and overall (Figure 3a) or according the HPV types (Figure 3b): HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, other
oncogenic HPV types and non-oncogenic HPV types.
doi: 10.1371/journal.pone.0079260.g003
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FUTURE I study reported persistence of 12 months or more
and the highest risk of progression to CIN2+ for HPV-16 and
HPV-33 [22].
HPV-18 is the second most prevalent HPV type in ICC after
HPV-16 [2,19]. The recent HERACLES/SCALE studies have
suggested that high grade pre-cancerous lesions associated
with HPV-18 are more likely to progress to cancer than lesions
associated with any other HPV type [23], and a Markov model
has also shown a higher risk of progression to later stages for
HPV-18 [24]. Our results also suggest that the carcinogenicity
of HPV-18 results from high rates of progression of HPV-18-
associated CIN3 to ICC, rather than from progression of
HPV-18 infection to pre-cancerous lesions.
The risk of developing a CIN was increased by co-infection.
Similarly, risk was increased by the presence of a separate
CIN1+; this was true regardless of whether the CIN1+ lesion
preceded the onset of the reference infection or whether it was
concomitant with the reference infection. Some studies have
shown that there is a higher chance of acquiring a new HPV
type if already infected [25–27], and one study has shown that
HPV-16 viral loads in lesions co-infected with other HPV types
were higher than in lesions infected with HPV-16 alone [28].
However, other studies have shown that infections with
Table 4. Multivariable analysis of the median time to clearance of cervical HPV infections: influence of HPV type, duration of
infection and previous and concomitant infection.
 Median time to clearance [1], months (inter-quartiles) Multivariable analysis of the chance of clearance2
  Hazard ratio p-value
  (95% CI)  
 16505 infections in 4793 women3
 10810 clearances
HPV type    
Non-oncogenic type 8.26 (5.97–17.57) 1 -
HPV-16 17.11 (7.80–30.26) 0.81 (0.75–0.88) <0.0001
HPV-18 11.84 (6.20–23.11) 0.93 (0.85–1.03) 0.1748
HPV-31 13.80 (6.43–28.89) 0.82 (0.74–0.90) <0.0001
HPV-33 12.00 (6.20–21.90) 0.95 (0.84–1.08) 0.4557
HPV-45 11.48 (6.20–23.31) 0.93 (0.80–1.08) 0.3465
Other oncogenic type 11.77 (6.20–20.03) 0.96 (0.91–1.02) 0.1739
 <0.0001 <0.0001
Duration of infection    
Transient 6.26 (5.70–8.16) 1 -
Less than 6MPI 11.02 (10.16–13.18) 0.40 (0.34–0.45) <0.0001
6MPI 18.85 (12.66–34.52) 0.14 (0.13–0.14) <0.0001
 <0.0001 <0.0001
Previous cervical HPV infection4    
No 11.25 (6.03–18.79) 1 -
Yes (same HPV type) 13.64 (6.43-NE) 0.58 (0.52–0.64) <0.0001
Yes (other HPV type[s]) 11.84 (6.23–22.43) 0.72 (0.68–0.77) <0.0001
 <0.0001 <0.0001
Cervical HPV co-infection5,6    
No - 1 -
Yes (at least 1 oncogenic HPV type) - 1.08 (1.01–1.14) 0.0146
Yes (only non-oncogenic HPV types) - 1.03 (0.93–1.15) 0.5501
 Not done4 0.0473
1 Time from first detection to first negative results
2 Covariates were included in the multivariable analysis if they had a global p-value of <0.2 (except region which was always included); covariates were: region, smoking,
age at first sexual intercourse, number of sexual partners during the past 12 months, history of Chlamydia trachomatis during the past 12 months, marital/partner status,
previous pregnancy, use of hormones for contraception or other indication, use of intrauterine device, previous or concomitant HPV co-infections, previous or concomitant
CIN1+. Refer to Table S8 for more detail.
3 Infections or clearances with a missing value for a covariate included in the analysis were excluded from the multivariable analysis.
4 Preceding the onset of the reference infection.
5 Following the onset of the reference infection and preceding its end.
6 Time-varying covariates: Kaplan-Meier analysis not done.
Values in italics show the log-rank p-value (for the median time to clearance) or the global p-value (for the multivariable analysis).
6MPI: 6-month persistent infection; HPV: human papillomavirus; NE: not estimated
doi: 10.1371/journal.pone.0079260.t004
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different oncogenic HPV types occur independently of one
another [29–31].
Consistent with the risk of progression to CIN, HPV-16 and
HPV-31 had the least chance of being cleared, followed by
HPV-33, HPV-18, HPV-45 and any other oncogenic type.
HPV-16 and HPV-31 have been previously reported to have
the lowest rates of clearance [32]. Previous infection
diminished the chance of clearance but, unexpectedly, co-
infection seemed to increase the chance. However, the
observed beneficial effect of co-infection was relatively weak
compared with the deleterious effect of previous infection. It is
paradoxical that co-infection increased the risk of progression
to a CIN but also increased the chance of clearance. There is
no clear explanation for these findings.
Several behavioural determinants were associated with
higher risk of progression from infection to lesion (tobacco
exposure, previous pregnancy, use of hormones and age at
first sexual intercourse) and lower chance of clearance of
infection (marital/partner status). An increased risk of cervical
abnormalities and/or cancer associated with these
determinants has been shown in other studies [6–8].
The analyses had some strengths and limitations. We
included only women with a confirmed HPV infection including
6MPI. The analysis therefore focused on factors that may
influence the risk of progression from infection to lesion, and
was not confounded by the risk of HPV acquisition. Another
major strength was that the PATRICIA study included a large
population with well-characterised virological and histological
samples and high follow-up rates over 48 months. Although the
study was multinational, involving women from many ethnic
groups, all participants followed the same protocol. The high
number of participants and length of follow-up allowed analysis
of CIN3+ lesions, which are a better predictor of ICC than
CIN2+ lesions [33]. Previous studies evaluating risk of
progression have had a smaller sample size and studied a
lower number of infections.
A limitation of the analysis is that misclassification of HPV
infection below the threshold for detection by PCR (a false-
negative result) might have overestimated rates of transient
HPV infection and underestimated 6MPI. Therefore, analyses
of clearance were done on subjects with two consecutive
negative PCR results (“confirmed clearance”). However, a
sensitivity analysis using a single negative PCR result gave
Figure 4.  Summary according to HPV type of prevalence in 6MPI, risk of progression to CIN3+ lesion and chance of
clearance.  Dark-shaded boxes: high prevalence (>10%), high risk of progression (HR >20) or low chance of clearance (HR <0.85)
Medium-shaded boxes: medium prevalence (5–10%), medium risk of progression (HR 5–20) or medium chance of clearance (0.85-
<0.95)
Light-shaded boxes: low prevalence (<5%), low risk of progression (HR <5) or high chance of clearance (HR ≥0.95)
Definitions of high, medium and low prevalence, risk of progression and chance of clearance are arbitrary and are based on the
results of the present study.
6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; HR: hazard ratio.
doi: 10.1371/journal.pone.0079260.g004
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very similar results (data not shown), demonstrating that the
risk of misclassification is low. As mentioned earlier, apparent
clearance could actually represent inability to detect the
infection. In addition, because pre-cancerous lesions may
develop over an extended period, the duration of which is
influenced by the HPV type the lesion is associated with, a
follow-up of 48 months will not allow detection of all lesions.
This may have led to underestimation of the progression rate of
some HPV types. A further limitation is that many women
started sexual activity before study enrolment and thus some
previous HPV infections would not have been recorded. Finally,
the study included only women aged 15–25 years, with six or
fewer lifetime sexual partners and no history of
immunosuppressive disease, limiting its generalizability; in
particular, age may have an important influence on the rate of
progression or clearance of HPV infection.
In conclusion, we have used data from the control arm of the
large, well-controlled PATRICIA study to evaluate the natural
history of progression of HPV infection to CIN lesion or to
clearance according to individual HPV type. Importantly, we
included CIN3, the immediate precursor lesion of cervical
cancer. A better understanding of the natural mechanisms of
progression to CIN lesions could contribute towards effective
implementation of HPV testing as part of screening for early
detection and prevention of cervical cancer, as recommended
by recent US guidelines [34]. Infection with oncogenic HPV
types increased the risk of development of CIN1+, CIN2+ or
CIN3+, the highest risk being associated with HPV-16 and
HPV-33, whilst infections with HPV types 16 and 31 had the
lowest likelihood of being cleared. The risk of progression was
increased as lesion severity increased, almost doubling from
CIN1+ to CIN2+ and from CIN2+ to CIN3+ for HPV types 16,
31, 33 and 45. We found that previous or concomitant HPV
infection or CIN1+ also increased the risk of progression to a
lesion, suggesting that multiple HPV infections could influence
progression. This finding is relevant to prevention of cervical
cancer, and deserves further investigation.
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